About InVivoSIM anti-human IL-23 (p19) (Guselkumab Biosimilar) This non-therapeutic biosimilar antibody uses the same variable regions as the therapeutic antibody Guselkumab making it ideal for research use. This Guselkumab biosimilar reacts with the p19 subunit of human IL-23. IL-23 is a heterodimeric cytokine composed of two disulfide-linked subunits, a p19 subunit that is unique to IL-23, and a p40 subunit that is shared with IL-12. IL-23 is secreted by activated dendritic cells and macrophages. IL-23 has been shown to enhance IFNγ production by memory T cells. Additionally, IL-23 induces the proliferation of memory T cells (but not naive T cells), whereas IL-12 has no effect on memory cells. IL-23 (but not IL-12) can also activate mouse memory T cells to produce the potent proinflammatory cytokine IL-17. IL-23 has been shown to be upregulated in certain autoimmune diseases and promote immunity in response to some viral and mycobacterial infections. Guselkumab targets the IL-23 p19 subunit preventing it from binding to cell receptors that would otherwise be activated by its presence. Guselkumab is used to treat moderate to severe plaque psoriasis, and psoriatic arthritis. InVivoSIM anti-human IL-23 (p19) (Guselkumab Biosimilar) Specifications IsotypeHuman IgG1, λ Recommended Isotype Control(s)RecombiMAb human IgG1 isotype control, anti-respiratory syncytial virus Recommended Dilution BufferInVivoPure pH 7.0 Dilution Buffer ImmunogenHuman IL-23 p19 Reported ApplicationsIL-23p19 neutralization Functional assays ELISA Western blot FormulationPBS, pH 7.0 Contains no stabilizers or preservatives Endotoxin<0.5EU/mg (<0.0005EU/μg) Determined by LAL gel clotting assay Aggregation<5% Determined by SEC Purity>95% Determined by SDS-PAGE Sterility0.2 μm filtration ProductionPurified from cell culture supernatant in an animal-free facility PurificationProtein A Molecular Weight150 kDa StorageThe antibody solution should be stored at the stock concentration at 4°C. Do not freeze.
